Round One Goes To Indian Cos As Roche Loses Patent Fight On Valcyte
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In a judgment that seasoned intellectual property experts predict will impact the course of Indian jurisprudence, the Indian Patent Office has rejected the patent claims of Swiss drug maker Roche over the antiviral drug Valcyte (valgancyclovir) mainly on grounds of lack of inventiveness
You may also be interested in...
Its Advantage Roche As Indian Patent Office Rejects Valcyte Opposition By Indian Groups
MUMBAI - Swiss drug maker Roche has gained a significant lead against two non-government organizations in its fight over patents of anti-infection drug Valcyte (valgancyclovir) after India's Controller of Patents rejected their pleas for pre-grant opposition
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).